NEWRON PHARMACEUTICALS SPA
- Country
- 🇮🇹Italy
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.newron.com
Clinical Trials
28
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (28 trials with phase data)• Click on a phase to view related trials
Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 138
- Registration Number
- NCT04461119
- Locations
- 🇺🇸
Behavioral Research Specialists, LLC, Glendale, California, United States
🇺🇸CBH Health, LLC, Gaithersburg, Maryland, United States
🇺🇸Community Clinical Research CCR, Austin, Texas, United States
An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects
- Conditions
- Healthy
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 6
- Registration Number
- NCT03446274
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, NG, United Kingdom
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
- Conditions
- Rett Syndrome
- Interventions
- First Posted Date
- 2016-06-03
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 129
- Registration Number
- NCT02790034
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of California, San Diego, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
- First Posted Date
- 2015-12-08
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 90
- Registration Number
- NCT02624167
- Locations
- 🇺🇸
Collaborative Neuroscience Network., Garden Grove, California, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States
🇮🇳KHM Hospital, Chennai, Tamil Nadu, India
A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 54
- Registration Number
- NCT01955564
- Locations
- 🇺🇸
Collaborative Neuroscience Network-Clinical Pharmacology Unit, Long Beach, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next